- Home
- MBRX vs LYRA Comparison
MBRX vs LYRA Comparison
Compare MBRX & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MBRX | LYRA |
|---|---|---|
| Founded | 2015 | 2005 |
| Country | United States | United States |
| Employees | 17 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1M | 5.6M |
| IPO Year | 2016 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MBRX | LYRA |
|---|---|---|
| Price | $2.01 | $1.28 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 1 |
| Target Price | ★ $105.50 | $16.00 |
| AVG Volume (30 Days) | ★ 239.2K | 66.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,534,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.25 | $0.08 |
| 52 Week High | $7.98 | $37.50 |
Technical Indicators
Market Signals| Indicator | MBRX | LYRA |
|---|---|---|
| Relative Strength Index (RSI) | 29.17 | 38.04 |
| Support Level | $0.37 | $1.21 |
| Resistance Level | $5.22 | $1.52 |
| Average True Range (ATR) | 0.18 | 0.14 |
| MACD | -0.05 | 0.05 |
| Stochastic Oscillator | 24.83 | 62.42 |
Price Performance
Historical ComparisonAbout MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.